Clinical Trial Update: A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating safety, pharmacokinetics, anti-drug antibodies, and anti-RSV antibodies after two doses of nirsevimab has completed and posted result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Nirsevimab (nirsevimab)

Snippet

Sponsor: AstraZeneca | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2026-04-16